Fulgent Genetics (NASDAQ:FLGT) Issues FY 2025 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of -0.650--0.65 for the period, compared to the consensus estimate of -0.660. The company issued revenue guidance of $310.0 million-$310.0 million, compared to the consensus revenue estimate of $310.4 million.

Fulgent Genetics Stock Up 19.1 %

FLGT traded up $3.29 during trading hours on Friday, hitting $20.54. The stock had a trading volume of 851,635 shares, compared to its average volume of 266,165. Fulgent Genetics has a 1 year low of $14.57 and a 1 year high of $25.11. The company's fifty day simple moving average is $17.46 and its 200 day simple moving average is $18.07. The stock has a market cap of $633.99 million, a PE ratio of -3.72 and a beta of 1.36.

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last posted its earnings results on Friday, May 2nd. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.22. The firm had revenue of $73.46 million during the quarter, compared to the consensus estimate of $71.26 million. Fulgent Genetics had a negative net margin of 59.39% and a negative return on equity of 1.81%. The company's revenue was up 14.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.01) earnings per share. As a group, equities analysts expect that Fulgent Genetics will post -0.85 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. StockNews.com upgraded Fulgent Genetics from a "sell" rating to a "hold" rating in a research report on Wednesday, March 5th. Piper Sandler reduced their target price on Fulgent Genetics from $22.00 to $16.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th.

Insider Buying and Selling

In other Fulgent Genetics news, CFO Paul Kim purchased 100,000 shares of the stock in a transaction on Wednesday, March 5th. The shares were purchased at an average price of $15.96 per share, with a total value of $1,596,000.00. Following the acquisition, the chief financial officer now directly owns 348,282 shares in the company, valued at approximately $5,558,580.72. The trade was a 40.28 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 31.76% of the stock is currently owned by insiders.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.